SCIENTIFIC PROGRAMME
SESSION I
THE GENOMIC AND
EPIGENOMIC LANDSCAPE
OF CLL AND CLINICAL
CONSEQUENCES
SESSION II
THE ROLE OF BCR
ACTIVATION AND
SIGNALLING FOR CLL
SESSION III
THERAPEUTIC OPTIONS
FOR CLL
SESSION IV
LONG TERM FOLLOW
UP OF CLINICAL TRIALS
VERSUS REAL WORLD
DATA (OUTSIDE CLINICAL
TRIALS DATA-OCT)
SESSION V
THE INCREASING ROLE
OF THE LEUKAEMIC
MICROENVIRONMENT
SESSION VI
THERAPEUTIC OPTIONS 2 :
THE USE OF CELLULAR
AND NON-CELLULAR
IMMUNOTHERAPIES IN
CLL
SESSION VII
EFFICACY THROUGH
SAFETY
SESSION VIII
CLONAL HETEROGENEITY,
CLONAL EVOLUTION AND
MECHANISMS OF DRUG
RESISTANCE
SESSION IX
CONTRASTING
THERAPEUTIC CONCEPTS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
FACULTY DISCLOSURES
future lies with the combination approaches which will allow to prevent emergence of
resistant clones and overcome tumor dependence on Bcl-2 family members.
References
1. Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, et al. AMG 176, a Selective
MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established
Therapies. Cancer Discov. 2018;8(12):1582-97. Epub 2018/09/27. doi: 10.1158/2159-8290.CD-18-0387.
PubMed PMID: 30254093.
2. Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-
specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat
Commun. 2018;9(1):5341. Epub 2018/12/19. doi: 10.1038/s41467-018-07551-w. PubMed PMID:
30559424; PubMed Central PMCID: PMCPMC6297231.
3. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of
apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell.
2006;10(5):375-88. Epub 2006/11/14. doi: 10.1016/j.ccr.2006.10.006. PubMed PMID: 17097560.
4. Gobessi S, Laurenti L, Longo PG, Carsetti L, Berno V, Sica S, et al. Inhibition of constitutive and
BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia
B cells. Leukemia. 2009;23(4):686-97. Epub 2008/12/19. doi: 10.1038/leu.2008.346. PubMed PMID:
19092849.
5. Paiva C, Rowland TA, Sreekantham B, Godbersen C, Best SR, Kaur P, et al. SYK inhibition thwarts
the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.
Haematologica. 2017;102(11):1890-900. doi: 10.3324/haematol.2017.170571. PubMed PMID:
28838991; PubMed Central PMCID: PMCPMC5664393.
6. Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, et al. An open-label phase 2 trial
of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.
Blood. 2015;125(15):2336-43. doi: 10.1182/blood-2014-08-595934. PubMed PMID: 25696919; PubMed
Central PMCID: PMC4401348.
7. Adam Kittai TH, Bria Thurlow, Basak Gokcora, Andrzej Stadnik, Renee MacKinnon, Stephen
Monette, Lacey Moore, Dan Persky, Byung Park, Stephen Spurgeon, Alexey Danilov. A PHASE I/II STUDY
OF THE SYK INHIBITOR ENTOSPLETINIB IN COMBINATION WITH OBINUTUZUMAB IN PATIENTS WITH
RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). EHA Library 2019.
8. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism
of chronic lymphocytic leukemia cell death. Blood. 2005;106(7):2513-9. Epub 2005/06/24. doi:
10.1182/blood-2005-04-1678. PubMed PMID: 15972445; PubMed Central PMCID: PMC1895272.
9. Gregory GP, Hogg SJ, Kats LM, Vidacs E, Baker AJ, Gilan O, et al. CDK9 inhibition by dinaciclib
potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell
lymphoma in vivo. Leukemia. 2015;29(6):1437-41. doi: 10.1038/leu.2015.10. PubMed PMID: 25578475;
PubMed Central PMCID: PMCPMC4498453.
10. Hashiguchi T, Bruss N, Best S, Lam V, Danilova O, Paiva CJ, et al. Cyclin-Dependent Kinase-9 Is
a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma. Mol Cancer Ther.
2019;18(9):1520-32. doi: 10.1158/1535-7163.MCT-18-1023. PubMed PMID: 31243099.
11. Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, San Martin M, et al. AZD4573 is a highly
selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells. Clin
Cancer Res. 2019. doi: 10.1158/1078-0432.CCR-19-1853. PubMed PMID: 31699827.
12. Phillips DC, Jin S, Gregory GP, Zhang Q, Xue J, Zhao X, et al. A novel CDK9 inhibitor increases
the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. Leukemia. 2019.
doi: 10.1038/s41375-019-0652-0. PubMed PMID: 31827241.